Department of Dermatology and Skin Science and Pathology and Laboratory Medicine, University of Bristish Columbia, Vancouver, BC.
J Cutan Med Surg. 2010 Jul-Aug;14(4):185-8. doi: 10.2310/7750.2010.09023.
pityriasis rubra pilaris (PRP) has unknown etiology and is often refractory to conventional therapies.
to document a PRP patient's response to adalimumab therapy and to highlight the potential role of tumor necrosis factor (TNF) in the development of PRP skin lesions.
a patient received adalimumab therapy at standard dosing intervals. In addition, the messenger ribonucleic acid (mRNA) of TNF in the lesional and perilesional normal skin was quantified in two patients with PRP.
the patient responded to adalimumab therapy and achieved clinical remission by 4 months. There was a significant elevation of TNF mRNA in the lesional skin of PRP.
TNF upregulation is detected in PRP lesional skin, consistent with the observed clinical efficacy of TNF blockade for the treatment of PRP.
毛发红糠疹（PRP）的病因不明，且常对常规治疗有抗性。
记录一位 PRP 患者对阿达木单抗治疗的反应，并强调肿瘤坏死因子（TNF）在 PRP 皮肤损伤发展中的潜在作用。
患者按标准剂量间隔接受阿达木单抗治疗。此外，对两名 PRP 患者的皮损和皮损旁正常皮肤中的 TNF 信使核糖核酸（mRNA）进行了定量。
患者对阿达木单抗治疗有反应，在 4 个月时达到临床缓解。PRP 皮损中的 TNF mRNA 显著升高。
在 PRP 皮损皮肤中检测到 TNF 的上调，这与 TNF 阻断治疗 PRP 的观察到的临床疗效一致。
